Altimmune (ALT) News Today → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free ALT Stock Alerts $10.18 +1.29 (+14.51%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAltimmune's (ALT) Buy Rating Reaffirmed at B. Rileyamericanbankingnews.com - March 29 at 4:51 AMAltimmune (NASDAQ:ALT) Shares Up 5.3%marketbeat.com - March 28 at 3:46 PMAltimmune (NASDAQ:ALT) Receives "Buy" Rating from B. Rileymarketbeat.com - March 28 at 12:33 PMAltimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 28 at 11:06 AMAltimmune says weight loss drug minimized muscle loss in trial results, which may set it apartmsn.com - March 28 at 8:41 AM7 Stocks That Will Drive the Weight Loss Drugs Market (ALT)marketbeat.com - March 28 at 7:22 AMQ4 2023 Altimmune Inc Earnings Callca.finance.yahoo.com - March 28 at 1:04 AMAnalysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)markets.businessinsider.com - March 27 at 8:40 PMBuy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass Preservationmarkets.businessinsider.com - March 27 at 8:40 PMAltimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Placeseekingalpha.com - March 27 at 7:50 PMAltimmune says weight loss drug minimized muscle loss in trial results that may set it apartcnbc.com - March 27 at 2:30 PMWhat To Know About Permvidutide—Altimmune Says Weight Loss Drug Minimized Muscle Mass Loss In Trialmsn.com - March 27 at 2:04 PMALT Stock Earnings: Altimmune Beats EPS for Q4 2023investorplace.com - March 27 at 12:05 PMAltimmune GAAP EPS of -$0.54 misses by $0.16msn.com - March 27 at 9:03 AMAltimmune Inc (ALT) Reports Q4 and Full Year 2023 Financial Results, Highlighting Pemvidutide's ...finance.yahoo.com - March 27 at 9:03 AMAltimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trialmsn.com - March 27 at 9:03 AMAltimmune falls after Q4 results; obesity drug data releasedmsn.com - March 27 at 9:03 AMAltimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 27 at 7:00 AMHere's what Wall Street expects from Altimmune's earnings reportmarkets.businessinsider.com - March 26 at 10:42 AMAltimmune (ALT) Scheduled to Post Quarterly Earnings on Wednesdayamericanbankingnews.com - March 25 at 2:00 AM(ALT) - Analyzing Altimmune's Short Interestbenzinga.com - March 22 at 4:30 PMAltimmune (ALT) Set to Announce Quarterly Earnings on Wednesdaymarketbeat.com - March 21 at 11:26 AMAltimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024globenewswire.com - March 20 at 7:30 AMAltimmune, Inc. (NASDAQ:ALT) Short Interest Down 6.4% in Februaryamericanbankingnews.com - March 19 at 3:26 AMA Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis - Anerveafinance.yahoo.com - March 18 at 9:10 PMShaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefrontseekingalpha.com - March 18 at 10:37 AMAltimmune, Inc. (NASDAQ:ALT) Short Interest Updatemarketbeat.com - March 18 at 8:52 AMMadrigal Stock Soars 12% After FDA Approved The First MASH Treatmentmsn.com - March 15 at 5:38 PMMadrigal Stock Soars 20% After FDA Approved The First MASH Treatmentmsn.com - March 15 at 1:18 PMAltimmune (NASDAQ: ALT)fool.com - March 15 at 12:36 PMAltimmune (NASDAQ:ALT) Trading Down 6.9%marketbeat.com - March 14 at 1:24 PMUroGen Pharma Q4 2023 Earnings Previewseekingalpha.com - March 13 at 5:57 PMBMO Hosts First Obesity Summit on Future of Obesity Care Marketfinance.yahoo.com - March 13 at 3:10 PMAltimmune (NASDAQ:ALT) Trading 6.3% Higher marketbeat.com - March 12 at 12:12 PMGSA Capital Partners LLP Grows Stake in Altimmune, Inc. (NASDAQ:ALT)marketbeat.com - March 10 at 7:41 AMAltimmune, Inc. (NASDAQ:ALT) Shares Sold by Connor Clark & Lunn Investment Management Ltd.marketbeat.com - March 9 at 5:00 AMROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALTprnewswire.com - March 5 at 5:30 PMLaurion Capital Management LP Has $2.11 Million Stock Holdings in Altimmune, Inc. (NASDAQ:ALT)marketbeat.com - March 5 at 2:39 PMAltimmune Stock (NASDAQ:ALT) Rides Volatility Wave Despite Promising Pipelinemsn.com - March 5 at 1:23 PMROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALTtheglobeandmail.com - March 3 at 8:40 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALTprnewswire.com - March 3 at 10:15 AMAltimmune, Inc. (NASDAQ:ALT) Short Interest Up 15.4% in Februarymarketbeat.com - March 3 at 6:58 AMHere's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Todaybenzinga.com - February 28 at 9:08 PMALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALTtheglobeandmail.com - February 28 at 10:55 AMThinking about buying stock in Intuitive Machines, SoundHound AI, Interactive Strength, Altimmune, or NanoVibronix?morningstar.com - February 28 at 8:39 AMAltimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rallyseekingalpha.com - February 27 at 11:12 AMLLY Apr 2024 665.000 putfinance.yahoo.com - February 27 at 12:11 AMLLY Mar 2024 900.000 putca.finance.yahoo.com - February 26 at 7:11 PMAltimmune Stock Surges, Kerrisdale Remains Short: What You Need To Knowmsn.com - February 26 at 1:39 PMStock Traders Buy High Volume of Call Options on Altimmune (NASDAQ:ALT)marketbeat.com - February 26 at 11:53 AM Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address A lot of people are making this costly mistake (Ad)You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one ALT Media Mentions By Week ALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼-0.180.61▲Average Medical News Sentiment ALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼254▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Ventyx Biosciences News PepGen News Arbutus Biopharma News Corbus Pharmaceuticals News Longboard Pharmaceuticals News Avid Bioservices News Heron Therapeutics News KalVista Pharmaceuticals News Nuvation Bio News Phathom Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.